» Articles » PMID: 24673368

Impaired Health-related Quality of Life in Acute Myeloid Leukemia Survivors: a Single-center Study

Overview
Journal Eur J Haematol
Specialty Hematology
Date 2014 Mar 29
PMID 24673368
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The purpose of this study was to assess the impact of acute myeloid leukemia (AML) and its treatment on health-related quality of life (HRQOL) by comparing the HRQOL of AML survivors with the HRQOL in the general population.

Methods: Two HRQOL questionnaires (EQ-5D and QLQ-C30) were sent to patients diagnosed with AML between 1999 and 2011 at a single academic hospital and still alive in 2012. HRQOL in AML survivors was compared with general population reference values. Multivariate analysis was used to identify factors associated with HRQOL in AML survivors.

Results: Questionnaires were returned by 92 of the 103 patients (89%). AML survivors reported significantly worse functioning, more fatigue, pain, dyspnea, appetite loss, and financial difficulties and lower EQ-VAS scores than the general population (P < 0.05). Impaired HRQOL in AML survivors was mainly found in survivors without a paid job. Other factors associated with a poor HRQOL were allogeneic hematopoietic stem cell transplantation and the absence of social support.

Conclusion: This single-center study showed that the HRQOL in AML survivors is worse than the HRQOL in the general population. HRQOL in these patients can be improved by adequately treating and preventing fatigue, pain, dyspnea, and appetite loss.

Citing Articles

Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia-a multi-centre randomised controlled trial to assess clinical and cost effectiveness: a study protocol for a randomised controlled trial.

Flett L, Abdelatif R, Baz S, Brady S, Corbacho B, Common K Trials. 2024; 25(1):427.

PMID: 38943201 PMC: 11214238. DOI: 10.1186/s13063-024-08272-w.


Trajectories of physical well-being among adults with acute myeloid leukemia.

Jensen-Battaglia M, Sohn M, Consagra W, Wang Y, Zhang Z, LoCastro M Blood Adv. 2024; 8(11):2612-2621.

PMID: 38429079 PMC: 11157208. DOI: 10.1182/bloodadvances.2023011804.


Economic and budgetary impact evaluation of isavuconazole (Cresemba®) versus voriconazole (Vfend®) for the treatment of patients with possible invasive aspergillosis from the perspective of the Brazilian supplementary health system.

Araujo G, Murta Amaral L, Ponzio V, Rocha J PLoS One. 2024; 19(3):e0299056.

PMID: 38427635 PMC: 10906891. DOI: 10.1371/journal.pone.0299056.


Pharmacoeconomic evaluation of isavuconazole, posaconazole, and voriconazole for the treatment of invasive mold diseases in hematological patients: initial therapy prior to pathogen differential diagnosis in China.

Han G, Xu Q, Lv Q, Li X, Shi X Front Public Health. 2024; 11:1292162.

PMID: 38179563 PMC: 10766362. DOI: 10.3389/fpubh.2023.1292162.


Impairment of vocational activities and financial problems are frequent among German blood cancer survivors.

Baum J, Lax H, Lehmann N, Merkel-Jens A, Beelen D, Jockel K Sci Rep. 2023; 13(1):22856.

PMID: 38129654 PMC: 10739705. DOI: 10.1038/s41598-023-50289-9.